Johnson & Johnson (JNJ) is a New Brunswick-based healthcare giant with a market cap of $402.8 billion. JNJ has outperformed the market in 2025, gaining 13.9% YTD and 2.1% over the past year, beating the S&P 500 Index.

Following impressive Q2 results, JNJ stock surged 6.2% in a single trading session. Total revenues increased 5.8% year-over-year to $23.7 billion, surpassing Street expectations. Analysts predict an 8.8% year-over-year growth in adjusted EPS for the full fiscal 2025.

JNJ’s stock maintains a consensus “Moderate Buy” rating with 10 “Strong Buys,” two “Moderate Buys,” and 12 “Holds.” Guggenheim analyst Vamil Divan raised the price target to $167, with a mean price target of $175.18 suggesting a 6.3% upside potential.

Analysts are slightly more bullish on JNJ, with a higher number of “Strong Buy” recommendations. The Street-high price target of $190 indicates a 15.3% premium to current levels. Aditya Sarawgi does not hold positions in any securities mentioned.

Read more at Yahoo Finance: Johnson & Johnson Stock: Analyst Estimates & Ratings